Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients

被引：0
|
作者：
Shen, Jingyi [1 ,2 ]
Shan, Meng [1 ,2 ]
Chu, Mengqian [1 ,2 ]
Cai, Yiming [1 ,2 ]
Rui, Jingwen [1 ,2 ]
Chen, Suning [1 ,2 ]
Wu, Depei [1 ,2 ]
Xu, Yang [1 ,2 ]
机构：
[1] Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
来源：
BLOOD CANCER JOURNAL | 2025年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
MUTATIONS; CBFB-MYH11; KIT; AML;
D O I：
10.1038/s41408-025-01227-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
    Zhang, Keyuan
    Zhang, Xiang
    Xu, Yang
    Xue, Shengli
    Qiu, Huiying
    Tang, Xiaowen
    Han, Yue
    Chen, Suning
    Sun, Aining
    Zhang, Yanming
    Wu, Depei
    Wang, Ying
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [2] Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
    Keyuan Zhang
    Xiang Zhang
    Yang Xu
    Shengli Xue
    Huiying Qiu
    Xiaowen Tang
    Yue Han
    Suning Chen
    Aining Sun
    Yanming Zhang
    Depei Wu
    Ying Wang
    Blood Cancer Journal, 13
  • [3] Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
    Wenxiu Shu
    Qianqian Yang
    Donghua He
    Yi Li
    Jing Le
    Qianqian Cai
    Hui Dai
    Liufei Luo
    Bingrong Chen
    Yuan Gong
    Dian Jin
    European Journal of Medical Research, 30 (1)
  • [4] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
    Brian A. Jonas
    Daniel A. Pollyea
    Leukemia, 2019, 33 : 2795 - 2804
  • [5] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
    Jonas, Brian A.
    Pollyea, Daniel A.
    LEUKEMIA, 2019, 33 (12) : 2795 - 2804
  • [6] Efficacy of hypomethylating agents and Venetoclax in unfit patients with acute myeloid leukemia
    Rieger, M.
    Manz, M. G.
    Muller, R.
    Theocharides, A. P. A.
    Schwotzer, R.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [7] Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Cherry, Evan M.
    Abbott, Diana
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Rosser, Julie
    Sato, Audrey
    Schowinsky, Jeffrey
    Inguva, Anagha
    Minhajuddin, Mohd
    Pei, Shanshan
    Stevens, Brett
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2021, 5 (24) : 5565 - 5573
  • [8] Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Berton, Guillaume
    Schaefer, Eva J.
    Zeidan, Amer M.
    Goldberg, Aaron
    Stein, Eytan
    Marcucci, Guido
    Bystrom, Rebecca P.
    Lindsley, R. Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony
    Pullarkat, Vinod
    Aldoss, Ibrahim
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Garciaz, Sylvain
    Ball, Brian
    Stahl, Maximilian
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1640 - 1643
  • [9] Original Safety and infection risk factors in elderly acute myeloid leukemia patients undergoing induction therapy with venetoclax combined with hypomethylating agents
    Zhu, Wenshan
    Zhu, Lijun
    Hu, Xing
    Chen, Erling
    Xue, Lei
    Wang, Xingbing
    Zhu, Xiaoyu
    Zheng, Changcheng
    Tong, Juan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (12): : 5897 - 5908
  • [10] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
    Albliwi, Moath
    Mustafa, Moaath K.
    Nurse, Daniel P.
    El-Asmar, Jessica
    Batah, Heya
    Abuamsha, Hasan
    Rauf, Asaad
    Hanna, John
    Abu-Farsakh, Yomna
    Bawwab, Ameed
    Zabor, Emily C.
    Bedelu, Yohana B.
    Chen, Mark Jinan
    Nakitandwe, Joy
    Jain, Akriti G.
    Gerds, Aaron T.
    Balderman, Sophia
    Molina, John C.
    Mukherjee, Sudipto
    Advani, Anjali S.
    Carraway, Hetty E.
    BLOOD, 2024, 144 : 1473 - 1474
12345